SYK trades 25.9% below Wall Street's consensus target of $387.46.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SYK achieves its forward estimates and maintains a stable P/E multiple of 20.5x. This scenario reflects the blended consensus of 51 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 21, 2026, Stryker Corporation (SYK) has a Wall Street consensus price target of $387.46, based on estimates from 51 covering analysts. With the stock currently trading at $307.80, this represents a potential upside of +25.9%. The company has a market capitalization of $117.88B.
Analyst price targets range from a low of $315.00 to a high of $465.00, representing a 39% spread in expectations. The median target of $394.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 37 analysts rating the stock as a Buy or Strong Buy,14 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, SYK trades at a trailing P/E of 36.6x and forward P/E of 20.5x. The forward PEG ratio of 1.38 indicates reasonable valuation for growth. Analysts expect EPS to grow +78.4% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $490.95, with bear and bull scenarios of $309.30 and $646.87 respectively. Model confidence stands at 55/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ZBHZimmer Biomet Holdings, Inc. | $17.2B | $87.97 | $96.33 | +9.5% | Hold | 10.4x | 42 |
BSXBoston Scientific Corporation | $67.3B | $45.29 | $82.90 | +83.0% | Buy | 13.5x | 44 |
EWEdwards Lifesciences Corporation | $50.4B | $87.36 | $96.55 | +10.5% | Buy | 29.0x | 48 |
BDXBecton, Dickinson and Company | $52.2B | $143.98 | $174.81 | +21.4% | Hold | 11.4x | 34 |
MDTMedtronic plc | $101.9B | $79.34 | $95.80 | +20.7% | Buy | 13.3x | 51 |
SNNSmith & Nephew plc | $12.8B | $30.08 | $30.93 | +2.8% | Hold | 13.6x | 22 |
HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
GMEDGlobus Medical, Inc. | $10.7B | $79.23 | $109.50 | +38.2% | Buy | 16.7x | 36 |
ATRCAtriCure, Inc. | $1.5B | $28.80 | $51.33 | +78.2% | Buy | 768.0x | 19 |
INVAInnoviva, Inc. | $1.7B | $22.49 | $37.00 | +64.5% | Buy | 6.3x | 10 |
Quick answers to the most common questions about buying SYK stock.
The consensus Wall Street price target for SYK is $387.46, representing 25.9% upside from the current price of $307.8. With 51 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
SYK has a consensus rating of "Buy" based on 51 Wall Street analysts. The rating breakdown is predominantly bullish, with 37 Buy/Strong Buy ratings. The consensus 12-month price target of $387.46 implies 25.9% upside from current levels.
SYK trades at a forward P/E of 20.5478x, representing a moderate valuation. With analysts targeting $387.46 (25.9% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $465 for SYK, while the most conservative target is $315. The consensus of $387.46 represents the median expectation. Our quantitative valuation model projects a bull case target of $647 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
SYK is heavily covered by Wall Street, with 51 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 36 have Buy ratings, 14 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SYK stock forecast based on 51 Wall Street analysts shows a consensus price target of $387.46, with estimates ranging from $315 (bear case) to $465 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $491, with bear/bull scenarios of $309/$647.
Our quantitative valuation model calculates SYK's fair value at $491 (base case), with a bear case of $309 and bull case of $647. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 55/100.
SYK trades at a forward P/E ratio of 20.5x based on next-twelve-months earnings estimates compared to a trailing P/E of 36.6x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on SYK, with a "Buy" consensus rating and $387.46 price target (25.9% upside). 37 of 51 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SYK analyst price targets range from $315 to $465, a 39% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $387.46 consensus represents the middle ground. Our model's $309-$647 range provides an independent fundamental perspective.
Deep dive into SYK consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.